Genitourinary Cancers | Emmanuel S Antonarakis, MD


Manage episode 235314716 series 1464173
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer — Part 1: Our one-on-one interview with Dr Antonarakis featuring emerging research and cases from his practice.

  • Initial evaluation of prognostic indicators in hormone-sensitive prostate cancer (HSPC) versus castration-resistant prostate cancer (CRPC) (0:00)
  • Effect of prostate-specific antigen (PSA) doubling time on time to metastasis and overall survival in nonmetastatic CRPC; improvement in metastasis-free survival with androgen receptor antagonist therapy (4:16)
  • Perspective on the use of intermittent androgen deprivation therapy (ADT) for patients with nonmetastatic HSPC and rising PSA levels (12:35)
  • Structural and mechanistic similarities and differences between available (apalutamide, enzalutamide) and investigational (darolutamide) androgen receptor antagonists (19:39)
  • Initial results of the Phase III ARAMIS trial: Metastasis-free survival improvement and tolerability of darolutamide versus placebo for nonmetastatic CRPC (22:41)
  • ARASENS: An ongoing Phase III trial evaluating darolutamide versus placebo in combination with standard ADT and docetaxel for patients with metastatic HSPC (25:38)
  • Perspective on the new drug application and potential FDA approval of darolutamide for nonmetastatic CRPC (27:02)
  • Spectrum and frequency of systemic and CNS-related side effects associated with apalutamide, enzalutamide and darolutamide (28:29)
  • Updated analysis of progression-free survival with first subsequent therapy (PFS2) in the SPARTAN study of apalutamide for high-risk nonmetastatic CRPC (31:50)
  • ARCHES: Design, efficacy and tolerability results from a Phase III trial of ADT with enzalutamide or placebo for metastatic HSPC (36:22)
  • Selection and sequencing of therapy for patients with metastatic prostate cancer (42:01)
  • Correlation between the presence of androgen receptor splice variant 7 (AR-V7) and outcomes with secondary hormonal therapy and chemotherapy in metastatic CRPC (45:58)
  • Prevalence and detection of AR-V7 in patients with metastatic CRPC (50:48)
  • Overview of BRCA1/2 and other DNA repair gene mutations that may confer sensitivity to PARP inhibition (54:32)
  • Efficacy and FDA breakthrough therapy designations for olaparib and rucaparib for metastatic CRPC (58:49)
  • GALAHAD: Preliminary results of a Phase II trial of niraparib for patients with metastatic CRPC and biallelic DNA repair gene defects (1:1:10)
  • Response to PARP inhibitor therapy in patients with metastatic CRPC with BRCA1/2 versus ATM mutations (1:4:06)
  • Activity of platinum-based chemotherapy in patients with metastatic CRPC and germline BRCA mutations (1:7:29)
  • Clinical experience with PARP inhibitor-associated side effects in men with metastatic CRPC (1:12:35)
  • Perspective on the negative results of the Phase III ERA 223 trial evaluating radium-223 dichloride in combination with abiraterone acetate for patients with chemotherapy-naïve metastatic CRPC and bone metastases (1:14:56)
  • Appropriate use of radium-223 for the treatment of symptomatic metastatic CRPC (1:19:54)
  • Biologic rationale for and ongoing investigation of lutetium-177-prostate-specific membrane antigen (PSMA)-617 for progressive PSMA-positive metastatic CRPC (1:23:03)
  • KEYNOTE-199: Updated analysis of a Phase II trial of pembrolizumab monotherapy for patients with metastatic CRPC previously treated with docetaxel (1:27:39)
  • Initial results of the Phase II CheckMate 650 trial of nivolumab with ipilimumab for metastatic CRPC (1:30:11)
  • Prevalence of microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) molecular phenotype and response to immune checkpoint blockade in patients with prostate cancer (1:35:02)
  • Emerging data with olaparib in combination with anti-PD-1/PD-L1 checkpoint blockade for metastatic CRPC (1:37:38)

Select publications

2173 episodes available. A new episode about every 0 hours averaging 74 mins duration .